Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - The market anticipates Inovio Pharmaceuticals (INO) to report a year-over-year increase in earnings despite lower revenues when it releases its quarterly results for June 2025 [1] Earnings Expectations - Inovio is expected to report a quarterly loss of $0.63 per share, reflecting a year-over-year change of +47.1% [3] - Revenues are projected to be $0.05 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 4.55% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Inovio is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +10.76% [11] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9] - Inovio currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - Inovio has beaten consensus EPS estimates three times over the last four quarters [13] - In the last reported quarter, Inovio was expected to post a loss of $0.74 per share but actually reported a loss of -$0.51, resulting in a surprise of +31.08% [12] Industry Context - Another company in the biomedical sector, VistaGen Therapeutics, is expected to report a loss of $0.47 per share, indicating a year-over-year change of -34.3% [17] - VistaGen's revenues are expected to be $0.65 million, up 712.5% from the previous year [17]